ROYALTY PHARMA PLC's ticker is RPRX and the CUSIP is G7709Q104. A total of 265 filers reported holding ROYALTY PHARMA PLC in Q4 2021. The put-call ratio across all filers is 0.25 and the average weighting 1.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $294,115 | -96.2% | 10,837 | -95.7% | 0.00% | -97.0% |
| Q2 2023 | $7,668,922 | +317.2% | 249,477 | +389.0% | 0.07% | +266.7% |
| Q1 2023 | $1,838,069 | -78.2% | 51,015 | -76.1% | 0.02% | -74.3% |
| Q4 2022 | $8,427,126 | +862.0% | 213,237 | +878.2% | 0.07% | +900.0% |
| Q3 2022 | $876,000 | -19.8% | 21,800 | -16.0% | 0.01% | -36.4% |
| Q2 2022 | $1,092,000 | -63.2% | 25,967 | -65.9% | 0.01% | -59.3% |
| Q1 2022 | $2,971,000 | +21.6% | 76,254 | +24.4% | 0.03% | +22.7% |
| Q4 2021 | $2,443,000 | +574.9% | 61,290 | +593.1% | 0.02% | +450.0% |
| Q2 2021 | $362,000 | -92.2% | 8,843 | -91.7% | 0.00% | -92.9% |
| Q1 2021 | $4,627,000 | +269.9% | 106,080 | +324.3% | 0.06% | +229.4% |
| Q4 2020 | $1,251,000 | -8.3% | 25,000 | -22.9% | 0.02% | -34.6% |
| Q3 2020 | $1,364,000 | – | 32,418 | – | 0.03% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| SIGULER GUFF ADVISERS, LLC | 6,761,970 | $244,378,000 | 79.54% |
| Vantage Consulting Group Inc | 7,862,542 | $284,152,000 | 60.85% |
| Memorial Sloan Kettering Cancer Center | 2,680,644 | $96,878,000 | 60.36% |
| Indie Asset Partners, LLC | 701,323 | $25,346,000 | 20.53% |
| HARVARD MANAGEMENT CO INC | 7,142,856 | $258,143,000 | 15.13% |
| Bleichroeder LP | 1,115,980 | $40,332,000 | 6.55% |
| Overbrook Management Corp | 785,132 | $28,375,000 | 6.16% |
| Geo Capital Gestora de Recursos Ltd | 194,305 | $7,022,000 | 3.21% |
| Brown University | 621,759 | $22,470,000 | 3.05% |
| Graypoint LLC | 610,584 | $22,067,000 | 2.71% |